MyPeptideMatchSurvodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis), demonstrating approximately 14.9% weight loss at 46 weeks in Phase 2b studies.
GLP-1/Glucagon Dual Agonist
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist in Phase 3 trials for obesity and MASH (metabolic-associated steatohepatitis), demonstrating approximately 14.9% weight loss at 46 weeks in Phase 2b studies.
Research Use Only — not intended for human consumption
Research peptides are sold for laboratory use only and are not intended for human consumption.
Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.
Week-by-week dosing protocolNo clinics in our directory yet. Browse all clinics.
Find a Peptide Clinic Near YouMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.